What changed
$MCK — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $96.3B | EPS $11.69 vs $11.57 🟢
💡 Consensus expects steady but unexciting earnings growth, pricing in a 20.6x P/E at historical median. Our variant view sees higher earnings growth from specialty margin expansion and share repurchases, leading to a forward P/E that is too low on revised estimates.
📉 Reward/risk: 1.95:1
🏢 Business Quality: 7/10 - Defensive cash flows dominant market position in pharma distribution, but low-margin model and regulatory overhang cap quality
📊 Valuation: fair - Current P/E 20.6x is in line with historical median (50th percentile).
🔮 Catalyst: Consensus estimate revision cycle following the beat
💰 Entry: $750.63, stop $715, target $820
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/MCK0619